However, mRNA vaccine-induced immune responses did not differ for those who developed myocarditis and those who did not<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Jan. 9, 2023 (HealthDay News) — Individuals who develop myocarditis following a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine have no difference in vaccine-induced immune responses compared with asymptomatic vaccinated controls, although free spike antigen is detected in those who develop vaccine-induced myocarditis, according to a study published online Jan. 4 in Circulation<\/em>.<\/p>\n Lael M. Yonker, M.D., from Massachusetts General Hospital in Boston, and colleagues prospectively collected blood from 16 patients who were hospitalized for myocarditis after SARS-CoV-2 mRNA vaccination. Extensive antibody profiling was performed and results were compared to those from 45 healthy, asymptomatic, age-matched vaccinated controls.<\/p>\n The researchers found that extensive antibody profiling and T-cell responses were essentially indistinguishable for individuals who developed postvaccine myocarditis and those of vaccinated controls, despite a modest increase in cytokine production. Individuals with postvaccine myocarditis had markedly elevated levels of full-length spike protein, unbound by antibodies, in their plasma, while no free spike was detected in asymptomatic vaccinated controls.<\/p>\n “Although the implications of this finding must be better understood, these results do not alter the risk-benefit ratio favoring vaccination against COVID-19 to prevent severe clinical outcomes,” the authors write.<\/p>\n Several authors disclosed financial ties to the biopharmaceutical industry.<\/p>\n